# A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.

> **NCT00432562** · PHASE1 · COMPLETED · sponsor: **Mast Therapeutics, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Breast Cancer
- Non-small Cell Lung Cancer
- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Vinorelbine Tartrate

## Key facts

- **NCT ID:** NCT00432562
- **Lead sponsor:** Mast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2007-11
- **Final completion:** 2007-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2012-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432562, "A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00432562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*